Scholarlink

<p>Skeletal muscle consists of a bundle of thousands of post-mitotic multinucleated cells (i.e., myofibers), in which myonuclei are evenly spaced and positioned at the periphery. This myonuclear positioning shapes myonuclear domain (MND) in myofibers, is essential for the transcriptional integrity of myofibers, is driven by the cytoskeleton and associated proteins and is required for proper myofiber functions. In numerous muscle diseases (i.e., myopathies), alteration of myonuclei localization contributes to myofiber dysfunction, supporting the need to better understand the fundamental mechanisms that regulate myonuclei dynamics in differentiated myofibers. In this study, we show that in Duchenne muscular dystrophy (DMD) myofibers, myonuclei are more dynamic and contribute to the failure in MND settings, suggesting enhanced myonuclear motility impacts myonuclear distribution. To identify new actors in MND settings, we performed a mass spectrometry (MS)-based proteomic analysis to identify microtubule-associated proteins (MAPs) in myotubes/myofibers and performed a siRNA screening on candidates. This approach highlighted NuMA1 as a new factor controlling myoblast fusion and myonuclear positioning through the control of nuclear-microtubule-organizing-center (n-MTOC) integrity and microtubule network orientation. Strikingly, while NuMA1 is restrained to myonuclei in mononucleated myoblasts, it progressively accumulates in the cytoplasm during muscle cell differentiation, preferentially with microtubule (MT) nucleation spots at the vicinity of the nuclear membrane. We identified that AMP Kinase activity has an essential role in NuMA1 nuclear/cytoplasmic accumulation through the specific phosphorylation on serine-1853 and the ability of myonuclei to accumulate NuMA1 is correlated to their motility in myofibers. Finally, we show that nuclear NuMA1 content is increased in DMD patients and <i>mdx</i> mouse model, contributing to more dynamic myonuclei that can be manipulated pharmacologically through the control of AMPK activity. Altogether, our data identifies a novel mechanism by which nuclear sequestration of a MAP allows to couple nuclear positioning and motion to MT organization along skeletal muscle differentiation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

NuMA1 controls myonuclear motility in striated skeletal muscle through AMPK activity and is impaired in Duchenne muscular dystrophy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月17日

查看全文
  • Nathalie Couturier,
  • Léa Castellano,
  • Alireza Ghasemizadeh,
  • Emilie Christin,
  • Muriel Sébastien,
  • Caroline E. Brun,
  • Damien Caillol,
  • Céline Malleval,
  • Alexandre Janin,
  • Gaëtan Juban,
  • Alexis Osseni,
  • Jean-Luc Thomas,
  • Stéphane Koenig,
  • Jessica Brunetti,
  • Alexandra Kraut,
  • Yohann Couté,
  • Nathalie Streichenberger,
  • Rémi Mounier,
  • Vincent Gache

摘要

Skeletal muscle consists of a bundle of thousands of post-mitotic multinucleated cells (i.e., myofibers), in which myonuclei are evenly spaced and positioned at the periphery. This myonuclear positioning shapes myonuclear domain (MND) in myofibers, is essential for the transcriptional integrity of myofibers, is driven by the cytoskeleton and associated proteins and is required for proper myofiber functions. In numerous muscle diseases (i.e., myopathies), alteration of myonuclei localization contributes to myofiber dysfunction, supporting the need to better understand the fundamental mechanisms that regulate myonuclei dynamics in differentiated myofibers. In this study, we show that in Duchenne muscular dystrophy (DMD) myofibers, myonuclei are more dynamic and contribute to the failure in MND settings, suggesting enhanced myonuclear motility impacts myonuclear distribution. To identify new actors in MND settings, we performed a mass spectrometry (MS)-based proteomic analysis to identify microtubule-associated proteins (MAPs) in myotubes/myofibers and performed a siRNA screening on candidates. This approach highlighted NuMA1 as a new factor controlling myoblast fusion and myonuclear positioning through the control of nuclear-microtubule-organizing-center (n-MTOC) integrity and microtubule network orientation. Strikingly, while NuMA1 is restrained to myonuclei in mononucleated myoblasts, it progressively accumulates in the cytoplasm during muscle cell differentiation, preferentially with microtubule (MT) nucleation spots at the vicinity of the nuclear membrane. We identified that AMP Kinase activity has an essential role in NuMA1 nuclear/cytoplasmic accumulation through the specific phosphorylation on serine-1853 and the ability of myonuclei to accumulate NuMA1 is correlated to their motility in myofibers. Finally, we show that nuclear NuMA1 content is increased in DMD patients and mdx mouse model, contributing to more dynamic myonuclei that can be manipulated pharmacologically through the control of AMPK activity. Altogether, our data identifies a novel mechanism by which nuclear sequestration of a MAP allows to couple nuclear positioning and motion to MT organization along skeletal muscle differentiation.